申联生物：拟2.37亿元收购世之源控股权并开展创新药业务

Core Viewpoint - The company plans to acquire a controlling stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. through its wholly-owned subsidiary, Shanghai Bentianc Biopharmaceutical Co., Ltd., using 237 million yuan of its own and raised funds [1] Group 1: Acquisition Details - The company will hold 51% of the equity in Shizhiyuan after the transaction, making it a controlled subsidiary [1] - The acquisition will be executed through equity transfer and capital increase [1] Group 2: Business Strategy - Following the completion of the acquisition, the company will fully develop its innovative drug business [1] - The company aims to establish a new pattern of dual main businesses, focusing on "human pharmaceuticals" and "animal health" [1]